MedPath

Somavaratan

Generic Name
Somavaratan
Drug Type
Biotech
CAS Number
1448335-08-7
Unique Ingredient Identifier
4Y05SI704S
Background

Somavaratan has been used in trials studying the treatment of Growth Disorders and Adult Growth Hormone Deficiency.

Clinical Trials
Related News

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Phase 3
Terminated
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2017-05-09
Last Posted Date
2018-03-09
Lead Sponsor
Versartis Inc.
Target Recruit Count
21
Registration Number
NCT03145831
Locations
🇺🇸

Eric Humphriss, Menlo Park, California, United States

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Phase 2
Terminated
Conditions
Adult Growth Hormone Deficiency (AGHD)
Interventions
First Posted Date
2016-03-25
Last Posted Date
2023-04-13
Lead Sponsor
Versartis Inc.
Target Recruit Count
36
Registration Number
NCT02719990

Versartis International Trial in Adults With Long-Acting Growth Hormone

Phase 2
Completed
Conditions
Adult Growth Hormone Deficiency
Interventions
First Posted Date
2015-08-18
Last Posted Date
2022-07-26
Lead Sponsor
Versartis Inc.
Target Recruit Count
36
Registration Number
NCT02526420
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇦🇺

St Vincent's Hospital, Fitzroy, Victoria, Australia

and more 15 locations

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Phase 2
Terminated
Conditions
Pediatric Growth Hormone Deficiency
Growth Disorders
Interventions
First Posted Date
2015-04-09
Last Posted Date
2022-07-25
Lead Sponsor
Versartis Inc.
Target Recruit Count
41
Registration Number
NCT02413138
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Japan

Long-Acting Growth Hormone in Children Compared to Daily rhGH

Phase 3
Completed
Conditions
Growth Disorders
Interventions
First Posted Date
2015-01-15
Last Posted Date
2022-12-30
Lead Sponsor
Versartis Inc.
Target Recruit Count
138
Registration Number
NCT02339090

Versartis Long-Term Safety Study of Somavaratan

Phase 2
Terminated
Conditions
Pediatric Growth Hormone Deficiency
Interventions
First Posted Date
2014-02-21
Last Posted Date
2018-03-09
Lead Sponsor
Versartis Inc.
Target Recruit Count
385
Registration Number
NCT02068521

VRS-317 in Adult Subjects With Growth Hormone Deficiency

Phase 1
Completed
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2011-05-24
Last Posted Date
2012-07-23
Lead Sponsor
Versartis Inc.
Target Recruit Count
50
Registration Number
NCT01359488
Locations
🇺🇸

Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy